Lectu re - UniversitätsSpital Zürich

Lecture
Cancer Center Zürich
Dienstag, 21. Juni 2016, 12.30–13.30 Uhr
Hörsaal WEST, UniversitätsSpital Zürich, Rämistrasse 100, 8091 Zürich
Snack ab 12.00 Uhr
Current treatment paradigms in
advanced prostate cancer
Joe O’Sullivan
Queen’s University Belfast, and the Northern Ireland Cancer Centre,
Belfast, Northern Ireland
Joe O’Sullivan graduated from the University College Dublin Medical School in 1993. After
specialist training in Dublin, he became a clinical research fellow at The Academic Urology Unit of
the Royal Marsden Hospital, where he completed an MD on the subject of bone seeking
radionuclide therapy in metastatic castration-resistant prostate cancer.
In 2004, Professor O’Sullivan was appointed Senior Lecturer and Consultant in Clinical Oncology
at The Centre for Cancer Research and Cell Biology at Queen’s University Belfast, and the
Northern Ireland Cancer Centre, Belfast. He was appointed Professor of Radiation Oncology at
Queen’s University Belfast in October 2011, and became the Clinical Director of Oncology at the
Belfast Health and Social Care Trust in September 2014.
Professor O’Sullivan leads the radiation oncology and prostate cancer clinical research groups at
the Northern Ireland Cancer Centre and is currently principal investigator on more than 10 clinical
trials. His research interests include castration-resistant prostate cancer, bone-seeking
radionuclide therapy, irradiation for macular degeneration, and translational research in radiation
and prostate cancer, and he has published widely in these areas.
Es ist keine Anmeldung notwendig. Die Teilnahme ist kostenlos.
Mit freundlicher Unterstützung von Bayer (Schweiz) AG
Organisation: Cancer Center Zürich, UniversitätsSpital Zürich,
Prof. Dr. Rolf Stahel, Leiter Cancer Center Zürich,
PD Dr. Irene A. Burger, Klinik für Nuklearmedizin,
Rämistrasse 100, 8091 Zürich
www.fortbildung.usz.ch | [email protected] | +41 44 255 30 35